Daily Derm Times: February 27, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Christophe Piketty, MD, PhD: The Role of Nemolizumab in Addressing Unmet Needs of Patients With AD and PN

Christophe Piketty, MD, PHD, provides a deeper look at the promise of nemolizumab in addressing unmet needs faced by patients with atopic dermatitis and prurigo nodularis.

Interview Intersection: Expert Interviews From February 2025

Dermatology Times is recapping our top expert interviews from the month of February.

A Case-Based Approach to Topical and Nonsteroidal AD Management

Nonsteroidal AD therapies are gaining attention due to their rapid effectiveness and ability to offer an alternative to long-term steroid use.

LEO Pharma Reports Positive Results in Delgocitinib Trial for CHE

DELTA China follows the success of European and Canadian trials, reinforcing delgocitinib’s potential as a global treatment for CHE.

The Importance of Community in Health Care

Independent pharmacies are closing at high rates, leaving many communities without essential health care access.

Quoin Reports Positive QRX003 “Whole Body” Pediatric Data for Netherton Syndrome

After just 2 weeks of twice-daily use, a pediatric patient saw visually improved skin with no adverse events.

Dermatology Times February 2025 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of February.

A “Step-Down” Approach May Be More Effective for Younger Patients with Psoriasis

Belgian patients receiving biologics had faster response rates compared to phototherapy, systemic, and topical treatments.

Are AD Severity Tools Essential in Routine Practice?

Objective tools like IGA and EASI provide structured severity assessment but often lack patient-reported insights such as itch severity.